Luminari CRO adds Rodecki and Yablon to growth team

Luminari CRO said June 17 it added Dr. Anna Rodecki and Jeffrey Scott Yablon to its business development and strategic advisory team. The hires are meant to speed clinical development, strengthen partnerships and expand the company’s AI-enabled clinical and regulatory offering.

Why it matters: - Luminari CRO is signaling a push to grow its footprint with leaders who have deep experience in clinical development, partnerships and life sciences operations. - The company is tying that growth strategy to AI-enabled clinical and regulatory intelligence, a capability it says can improve development decisions and reduce complexity for sponsors.

What happened: - Luminari CRO announced the appointments of Dr. Anna Rodecki and Jeffrey Scott Yablon on June 17, 2026. - The company is based in Wheeling, Illinois. - Rodecki and Yablon joined the company’s business development and strategic advisory team. - Luminari CRO supports biotechnology, pharmaceutical and other life sciences companies.

The details: - Rodecki brings nearly 20 years of experience across clinical development, operational execution, portfolio strategy, feasibility, trial execution and organizational transformation. - Her background spans biopharma, medical technology and emerging biotechnology companies. - Rodecki has advised executive teams on development strategy, commercialization readiness, risk management and clinical operations. - Her work has focused on accelerating patient access, improving development productivity and reducing execution risk. - Rodecki has also explored AI-enabled drug development, precision medicine, protocol optimization, feasibility intelligence and the economics of clinical research. - At Luminari CRO, Rodecki will support organizations aiming to make better decisions and execute with greater certainty. - Yablon joins as Strategic Advisor and Champion. - Yablon brings more than 25 years of global life sciences leadership across biotechnology, pharmaceuticals, CROs and technology-enabled clinical development organizations. - His previous senior roles included president and CEO of Jigsaw Clinical Research, plus leadership posts at PAREXEL, ICON, Cognizant Life Sciences, ArisGlobal, Frontage Laboratories and TAP Pharmaceuticals. - Yablon’s experience includes clinical development strategy, strategic partnerships, business development, biometrics, regulatory planning and operational execution in North America, Europe and Asia. - Luminari CRO said Yablon will work with life sciences organizations seeking to use AI-enabled clinical and regulatory intelligence to accelerate timelines and improve decision-making. - CEO Yuri Zamostin said the combined expertise of Rodecki and Yablon will help sponsors bring innovation to patients faster and more efficiently. - Luminari CRO says the appointments reinforce its mission to provide strategic, responsive and technology-forward support in a complex clinical research and regulatory environment.

Between the lines: - The hires suggest Luminari CRO is trying to compete on strategy as much as on execution, pairing business development with advisory credibility. - The emphasis on AI indicates the company is positioning itself around workflow modernization, not just traditional CRO services. - The announcement also reflects broader industry pressure to shorten development cycles and improve the economics of clinical research.

What's next: - Luminari CRO is likely to use the new appointments to deepen sponsor relationships and pursue additional partnerships. - The company also appears set to keep expanding its AI-enabled clinical and regulatory intelligence capabilities. - More information is available on the company’s LinkedIn page.